Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $1 |
| % Margin | – | – | – | 74.6% |
| R&D Expenses | $1 | $1 | $1 | $2 |
| G&A Expenses | $1 | $1 | $2 | $1 |
| SG&A Expenses | $1 | $1 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $3 | $3 |
| Operating Income | -$2 | -$3 | -$3 | -$3 |
| % Margin | – | – | – | -375.6% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$2 | -$3 | -$3 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$3 | -$3 | -$3 |
| % Margin | – | – | – | -350.2% |
| EPS | -0.19 | -0.34 | -0.45 | -0.52 |
| % Growth | 44.1% | 24.4% | 13.5% | – |
| EPS Diluted | -0.19 | -0.34 | -0.45 | -0.52 |
| Weighted Avg Shares Out | 11 | 9 | 6 | 6 |
| Weighted Avg Shares Out Dil | 11 | 9 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$3 | -$3 | -$3 |
| % Margin | – | – | – | -369.4% |